BALTIMORE, Md.—The novel therapeutic agent PA65020 (enteric-coated aspirin plus immediate-release omeprazole) significantly reduced gastrointestinal mucosal damage after 28 days of treatment compared ...

This was a post hoc analysis of the 2021 open-label randomized ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness) trial that showed no statistical ...

Opting for enteric-coated aspirin over the uncoated pills doesn’t appear to have a major impact on the drug’s antiplatelet effects in patients with atherosclerotic CVD, but nor did it offer an edge in ...

Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers Results of a PA32540 Phase 3 Post-Hoc ...

Aspirin resistance is an almost nonexistent phenomenon, one group of pharmacologists is claiming [1]. In a study of 400 healthy individuals, they demonstrate that what appears to be "aspirin ...

Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and ...

Is it resistance or pseudoresistance? According to a new study published in Circulation, aspirin resistance may be a myth, an artifact of the enteric coating of most aspirin tablets. The coating, ...

SPARTA, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected ...